Crinetics Pharmaceuticals Inc. has announced the initiation of the BALANCE-CAH Phase 2/3 clinical trial evaluating atumelnant, an investigational oral adrenocorticotropic hormone (ACTH) receptor antagonist, for the treatment of classic congenital adrenal hyperplasia $(CAH)$ in children and adolescents. The study, which recently dosed its first patient, is structured in three parts: an open-label, dose-ranging Phase 2 segment; a double-blind, randomized, placebo-controlled Phase 3 segment; and an open-label extension. Atumelnant is the first small molecule ACTH receptor antagonist in late-stage development for this indication and has received Orphan Drug Designation from the U.S. Food & Drug Administration. Study results have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9630985-en) on January 22, 2026, and is solely responsible for the information contained therein.